Skip to main content
NAMS
NASDAQ Life Sciences

Chief Accounting Officer Louise Kooij to Depart NewAmsterdam Pharma

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$29.72
Mkt Cap
$3.474B
52W Low
$16.785
52W High
$42
52W Position info
77% above low
Off High info
29% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

NAMS sits 77% above its 52-week low of $16.785.

Summary

NewAmsterdam Pharma announced that Chief Accounting Officer Louise Kooij will depart the company effective August 31, 2026, with a separation agreement in place.


Key Events · Executive and Board Changes · NAMS

  • Chief Accounting Officer Departure

    Louise Kooij will step down as Chief Accounting Officer effective August 31, 2026, by mutual agreement.

  • Separation Agreement Terms

    Ms. Kooij will receive a lump sum equal to 12 months of her base salary, a pro-rated 2026 annual cash bonus, and accrued holiday/vacation days.

  • Equity Vesting Extended

    Vesting of outstanding stock options and restricted stock units (RSUs) will be extended through January 10, 2027, with an exercise period until February 10, 2027.

  • Restrictive Covenants

    The separation agreement includes confidentiality, non-compete, non-disparagement covenants, and a release of claims.


Analysis · NAMS · Life Sciences

The departure of a Chief Accounting Officer, even if amicable and planned, introduces a transition period for a key financial role. The company has outlined a standard separation package, including a lump sum, pro-rated bonus, and extended equity vesting, which aims to ensure an orderly transition and adherence to restrictive covenants. Investors will monitor the appointment of a successor and any potential impact on financial reporting.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAMS was trading at $29.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $16.79 to $42.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $20.10 info
Change: -$0.590 (-3%) info
Market Cap: $2.415B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $20.10 info
Change: -$0.140 (-0.69%) info
Market Cap: $2.415B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $20.10 info
Change: -$3.61 (-15%) info
Market Cap: $2.415B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $20.10 info
Change: -$3.22 (-14%) info
Market Cap: $2.415B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $20.10 info
Change: -$2.72 (-12%) info
Market Cap: $2.415B info